
WE CLAIM:

1. A compound of Formula (I-D):



Formula (I-D)

or a pharmaceutically acceptable salt thereof:

wherein:

R^2 is hydroxy, halogen, cyano, cyanomethyl, -$(NR^4)_2$, hydroxy(C1-C12)alkyl, C1-C6alkoxy, -SO_2(C1 – C3alkyl), (C6-C14arylC1-C3alkyl)-X-, hetero(C3-C12alkyl), C2- C4 alkynyl, halo(C1-C12alkyl)-X-, (C1 – C5 alkyl)-X-, (C1 – C5 alkyl)-Z-, 5-10 membered heterocyclyl, (C3-C12cycloalkyl)-L-X-, (C3-C12cycloalkyl)-Z-, (C6-C14aryl)-X-, (C6-C14 aryl)-Z-, or (5-14 membered heteroaryl)-X-, wherein the heterocyclyl, the cycloalkyl, the aryl and the heteroaryl are optionally substituted with one or more R^5;

each X is independently a bond, O, S, -NR^4- or -NR^4C(O)-;

each Z is independently a bond, -SO-, -SO_2-, -CH(OH)- or -C(O)-;

each L is independently a bond or C1 – C3 alkylene;


each R^4 is independently hydrogen or C1 – C3 alkyl;


each R^5 is independently cyano, oxo, halogen, C1 – C3 alkyl, hydroxy(C1-C12alkyl), C1-C6alkoxy, halo(C1-C12alkyl)-X-, (C3-C12cycloalkyl)-Z-, (C6-C14arylC1-
























C3alkyl)-X-, (C6-C14arylC1-C3alkyl)-X-, wherein the aryl is substituted with cyano, (C3-C12cycloalkyl)-L-X-, (5-14 membered heteroaryl)-L-X-, and the heteroaryl is optionally substituted with one or more C1-C3alkyl or oxo, or (C6-C14aryl)-X-; and

R^6 is hydrogen, halogen, C1-C3 alkyl, halo(C1-C12alkyl) or C1-C6alkoxy.

2. A compound selected from:































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,
























,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,















,

,


















,






,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,






















,

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




























,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
















































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,






,

,

,

,

,

,

,

,

,

,

, or





,

,

,

,

,

,

,

or a pharmaceutically acceptable salt thereof.

3. Compound of formula:


.

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition, comprising a compound of Formula (I-D) according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

5. Use of a therapeutically effective amount of a compound of Formula (I-D) according to any one of claims 1-3 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.


6. The use of claim 5, wherein the therapeutically effective amount of the compound is between 0.01 to 300 mg/kg per day.

7. The use of claim 5, wherein the therapeutically effective amount of the compound is between 0.1 to 100 g/kg per day.

8. The use according to any one of claims 5-7, wherein the cancer is selected from the group consisting of Cardiac; Lung; Gastrointestinal; Genitourinary tract; Liver; Biliary tract; Bone; Nervous system; Gynecological; Hematologic; Skin; and Adrenal glands.


9. The use according to any one of claims 5-7, wherein the cancer is a MTAP-associated cancer.

10. The use of claim 6, wherein the cancer is hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.
11. Compound of formula:




or a pharmaceutically acceptable salt thereof.

12. A pharmaceutically acceptable salt of




.

13. The use of claim 5, wherein the compound is




or a pharmaceutically acceptable salt thereof.

14. The use of claim 5, wherein the compound is



.

15. The use of claim 5, wherein the compound is a pharmaceutically acceptable salt of a compound of the formula



.

16. The use of claim 5, wherein the cancer is selected from the group consisting of sarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma, bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma, esophagus, stomach, pancreas, small bowel, large bowel, kidney, bladder and urethra, prostate, testis, hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma, osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors, skull, meninges, brain,

uterus, vulva, vagina, fallopian tubes, blood, Hodgkin's disease, non-Hodgkin's lymphoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, and neuroblastoma.